Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Equity Ratio (2016 - 2026)

Heron Therapeutics filings provide 16 years of Equity Ratio readings, the most recent being 0.04 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 130.75% to 0.04 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.04, a 130.75% increase, with the full-year FY2025 number at 0.06, up 138.81% from a year prior.
  • Equity Ratio hit 0.04 in Q1 2026 for Heron Therapeutics, down from 0.06 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.09 in Q1 2022 to a low of 0.2 in Q2 2023.
  • Median Equity Ratio over the past 5 years was 0.12 (2025), compared with a mean of 0.07.
  • Biggest five-year swings in Equity Ratio: plummeted 382.32% in 2023 and later surged 138.81% in 2025.
  • Heron Therapeutics' Equity Ratio stood at 0.05 in 2022, then plummeted by 382.32% to 0.15 in 2023, then rose by 5.47% to 0.14 in 2024, then skyrocketed by 138.81% to 0.06 in 2025, then plummeted by 33.75% to 0.04 in 2026.
  • The last three reported values for Equity Ratio were 0.04 (Q1 2026), 0.06 (Q4 2025), and 0.06 (Q3 2025) per Business Quant data.